Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) PT at $8.83

Shares of ProQR Therapeutics (NASDAQ:PRQR) have received a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.83.

PRQR has been the subject of several recent research reports. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th.

ProQR Therapeutics Trading Down 8.6 %

Shares of NASDAQ PRQR opened at $2.13 on Tuesday. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The company has a market cap of $173.98 million, a P/E ratio of -6.66 and a beta of 0.25. The stock has a fifty day moving average price of $2.40 and a 200 day moving average price of $2.64.

Hedge Funds Weigh In On ProQR Therapeutics

Several large investors have recently modified their holdings of the stock. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter worth about $39,000. Woodline Partners LP acquired a new stake in ProQR Therapeutics during the fourth quarter worth about $9,426,000. Velan Capital Investment Management LP acquired a new stake in ProQR Therapeutics during the fourth quarter worth about $107,000. Squarepoint Ops LLC raised its stake in ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 11,623 shares during the period. Finally, Two Sigma Investments LP raised its stake in ProQR Therapeutics by 512.8% during the fourth quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock worth $1,015,000 after acquiring an additional 320,614 shares during the period. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).